After recalibrating its production strategy in the late 2010s to help meet the realities of the CAR-T market, Gilead Sciences’ Kite Pharma is preparing to hit the ground running with the potential approval of a next-generation multiple myeloma cell therapy later this year.
With ‘lessons learned,’ Kite prepares to hit the ground running as next-gen CAR-T decision looms
Latest from Blog
Minnesota reaches $18.5 million settlement with nonprofit over child nutrition fraud claims
Partners in Nutrition will dissolve and turn over remaining funds under a consent judgment filed in Hennepin County Post Views: 1
Caitlin Clark turns cereal into a $100,000+ fundraiser: How the WNBA superstar used her platform to support youth programmes away from basketball
Caitlin Clark’s rise has translated off the court as the Indiana Fever star has made more of herself through commercial partnerships and community endeavors. One of the more unique examples has been
The Healthiest Vegetables to Add to Your Grocery List, According to Dietitians
Fresh or frozen, these veggies are a simple way to add fiber and essential vitamins to your diet. Post Views: 1
